Abstract
A series of diflunisal 4-thiazolidinones were synthesized. Some selected compounds were determined at one dose towards the full panel of 60 human cancer cell lines by National Cancer Institute. 2',4'-Difluoro-4-hydroxy-N-[4-oxo-2-(thiophen-2-yl)-1,3-thiazolidin-3-yl]biphenyl- 3-carboxamide (4a) demonstrated the most marked effect on K-562 cancer cell line with 58.59 % growth inhibition at 10 μM. Compound 4a was evaluated in vitro using the MTT colorimetric method against human leukemia cell line K-562 and mouse embryonic fibroblasts cell line NIH- 3T3 at different doses for cell viability and growth inhibition. Compound 4a exhibited anticancer activity with IC50 value of 5.2 μM against K-562 cells and did not display cytotoxicity towards NIH-3T3 cells compared with diflunisal. In addition, this compound could be an interesting prototype as an antiproliferative agent.
Keywords: Annexin-V, apoptosis, diflunisal, K-562 cancer cell line, 4-Thiazolidinone.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Synthesis of Diflunisal Thiazolidinones as Anticancer Agents
Volume: 16 Issue: 10
Author(s): Sevil Şenkardeş, Özlem B. Özakpınar, Derya Özsavcı, Azize Şener, Özge Çevik and Ş. Güniz Küçükgüzel
Affiliation:
Keywords: Annexin-V, apoptosis, diflunisal, K-562 cancer cell line, 4-Thiazolidinone.
Abstract: A series of diflunisal 4-thiazolidinones were synthesized. Some selected compounds were determined at one dose towards the full panel of 60 human cancer cell lines by National Cancer Institute. 2',4'-Difluoro-4-hydroxy-N-[4-oxo-2-(thiophen-2-yl)-1,3-thiazolidin-3-yl]biphenyl- 3-carboxamide (4a) demonstrated the most marked effect on K-562 cancer cell line with 58.59 % growth inhibition at 10 μM. Compound 4a was evaluated in vitro using the MTT colorimetric method against human leukemia cell line K-562 and mouse embryonic fibroblasts cell line NIH- 3T3 at different doses for cell viability and growth inhibition. Compound 4a exhibited anticancer activity with IC50 value of 5.2 μM against K-562 cells and did not display cytotoxicity towards NIH-3T3 cells compared with diflunisal. In addition, this compound could be an interesting prototype as an antiproliferative agent.
Export Options
About this article
Cite this article as:
Şenkardeş Sevil, Özakpınar B. Özlem, Özsavcı Derya, Şener Azize, Çevik Özge and Küçükgüzel Güniz Ş., Synthesis of Diflunisal Thiazolidinones as Anticancer Agents, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (10) . https://dx.doi.org/10.2174/1871520615666150831125337
DOI https://dx.doi.org/10.2174/1871520615666150831125337 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Naturally Occurring Hydroxytyrosol: Synthesis and Anticancer Potential
Current Medicinal Chemistry Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines
Current Topics in Medicinal Chemistry Immunity to Tumour Antigens
Current Pharmaceutical Design The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Nutraceuticals, A New Challenge for Medicinal Chemistry
Current Medicinal Chemistry Evaluating the Susceptibility of Mitochondrial DNA Germline Mutations in Chinese Cancer Patients
Current Molecular Medicine The Antitumor Efficiency of Zinc Finger Nuclease Combined with Cisplatin and Trichostatin A in Cervical Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results
Current Drug Targets Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine Nicotine Vaccines
CNS & Neurological Disorders - Drug Targets Psychological Adjustment of Women in Cervical Cancer Screening
Current Women`s Health Reviews Editorial [Hot Topic: The RB-Pathway in Cancer (Executive Editor: Erik Knudsen)]
Current Molecular Medicine Antitumoral Potential of Snake Venom Phospholipases A2 and Synthetic Peptides
Current Pharmaceutical Biotechnology Transdermal Oxandrolone: Ex Vivo Percutaneous Absorption Study
Current Drug Delivery Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Teratogenic Activity of HDAC Inhibitors
Current Pharmaceutical Design In Silico Studies Most Employed in the Discovery of New Antimicrobial Agents
Current Medicinal Chemistry Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology